BOSTAN, H. Et Al. 2020. Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.12 , 836-842.

BOSTAN, H., TOPTAŞ, T., Tanrikulu, F. P., Kut, K., Arikan, F., Yilmaz, F., ... ATAGÜNDÜZ, I.(2020). Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.12, 836-842.

BOSTAN, HAYRİ Et Al. "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.12, 836-842, 2020

BOSTAN, HAYRİ Et Al. "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.12, pp.836-842, 2020

BOSTAN, H. Et Al. (2020) . "Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.20, no.12, pp.836-842.

@article{article, author={HAYRİ BOSTAN Et Al. }, title={Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2020, pages={836-842} }